The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Symposium | Looking to the future of bispecific antibodies in MM, and panelist Q&A
Sagar Lonial
Amrita Krishnan
Sergio Giralt
Naresh Bumma
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In a cross-sectional analysis of 11 trials, what was the incidence of Grade 3/4 infections following treatment with anti-BCMA versus non-BCMA antibodies?
A
B
C
D
Video series
The Multiple Myeloma Hub virtual symposium held on March 11, 2024,“Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” concluded by looking to the future of T-cell engagers in multiple myeloma, delivered by chair Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US.
Lonial shared his future perspectives for the treatment of relapsed/refractory multiple myeloma, including strategies for managing resistance to B-cell maturation antigen, alternative treatments for anti-BCMA exposed patients, and the potential of cereblon E3 ligase modulators (Figure 1).
Figure 1. Novel CELMoD agents in development*
CELMoD, cereblon E3 ligase modulators; CRBN, cereblon; MM, multiple myeloma.
*Data from Rajkumar, et al.1; Facon, et al.2; Durie, et al.3; Ito and Handa.4; Matyskiela, et al.5; Hansen, et al.6
†Iberdomide (IBER; CC-220) and mezigdomide (CC-92480) are investigational products that are currently not approved by any regulatory agency.
Q&A session
This symposium closed with a panel Q&A session with live audience participation. Our panelists shared their perspectives on key topics including health-related quality of life in patients treated with bispecific antibodies, highlighting the impact of reduced dosing frequencies, as well as subcutaneous versus intravenous administration, on the patient experience.
This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.
Q&A session
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
